Susceptibility of Gambian Adults to PfSPZ-Challenge Infection in the Controlled Human Malaria Infection Model (CHMI-Gambia1)

NCT03496454 NA COMPLETED

Controlled human malaria infection (CHMI) is an important tool for the assessment of the efficacy of novel malaria vaccines and drugs prior to field trials. CHMI also allows for the evaluation of immunity to malaria and parasite growth rates in vivo and thus allows for the assessment of the natural acquisition and loss of malaria immunity. This may be particularly useful in individuals from endemic areas with changing levels of exposure and immunity to malaria. Thus, CHMI in individuals with prior exposure to malaria could be a valuable tool to accelerate malaria vaccine development and inform malaria control programs of changing immunity levels and related disease presentations. In this trial, the investigators intend to study the effect of pre-exposure to Plasmodium falciparum (Pf) on parasite kinetics, clinical symptoms and immunity after CHMI by PfSPZ Challenge in Gambian adults. Based on a well-defined sero-profile representing the extremes of current malaria exposure in The Gambia, two cohorts will be identified to study the impact of naturally acquired immunity on susceptibility for a Controlled Human Malaria Infection.

Details

Lead sponsor	London School of Hygiene and Tropical Medicine
Phase	NA
Status	COMPLETED
Enrolment	19
Start date	Thu Mar 29 2018 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Wed Dec 05 2018 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Malaria

Interventions

• PfSPZ Challenge

Countries

The Gambia